Investigational New Drugs Publication

Apogee is pleased to announce a publication in “Investigational New Drugs” (abstract) that shows the synergy between ABC294640 and sorafenib in inhibiting tumor growth in animal models.

Dr. Lynn Maines of Apogee stated  “We have seen this synergism with ABC294640 and several other drugs that our currently the standard of care for various cancers as well as inflammatory diseases.  ABC294640 looks very promising not only as a stand alone agent but as an add on to current therapies due to its low toxicity and the several proliferative and inflammatory cascades it negatively influences in cancer and inflammation.”

Powered by THE BRAVO GROUP & ARCHODA: CREATE SOMETHING UNIQUE